---
title: May 2025
date: 2025-05-31
categories: [Newsletters]
tags: [AI in clinical trials, LLM, Patient Selection, Data Management ]
description: This issue explores the transformative impact of artificial intelligence (AI) across the clinical trial spectrum, highlighting innovations that enhance patient selection, data management, treatment effect estimation, knowledge synthesis, real-time monitoring, and trustworthiness. It emphasizes the ongoing challenges and future directions for AI integration in clinical research, focusing on explainability, validation, and regulatory compliance.
---

# Introduction

Innovations in artificial intelligence (AI) are systematically transforming the landscape of clinical research, offering new avenues for accelerating drug development and enhancing patient care. This issue explores how advanced AI methodologies are being deployed across the entire clinical trial spectrum, from the initial stages of protocol design and patient identification to real-time trial execution and post-market safety surveillance. Contributions detail progress in leveraging large language models (LLMs) for precise patient phenotyping and automated trial matching, alongside breakthroughs in secure data management through synthetic data generation and federated learning. Further advancements in causal AI provide robust frameworks for estimating treatment effects in complex real-world settings, while AI-powered automation streamlines clinical knowledge synthesis. The integration of AI with wearable technologies also enables real-time patient monitoring, ensuring enhanced safety and data reliability. A consistent focus across these domains is the imperative for trustworthiness and interpretability, crucial for clinical adoption and regulatory acceptance.

# AI for Precision Patient Selection and Optimized Clinical Trial Design

Clinical trials are foundational to medical advancement, yet they often face significant challenges, including protracted recruitment periods, patient heterogeneity, and the complexities of identifying optimal treatment responses. Artificial intelligence (AI), particularly large language models (LLMs) and advanced machine learning techniques, is poised to revolutionize this landscape by enhancing patient identification, stratification, and the design of more targeted and efficient trials. These advancements aim to improve patient access to novel therapies, accelerate drug development, and facilitate the realization of personalized medicine.

## Contextual Patient Phenotyping and Stratification

A cornerstone of precision medicine is the ability to accurately phenotype patients into homogeneous subgroups, leading to more robust clinical trial designs with reduced variability and potentially enhanced treatment effect sizes. Traditional clustering methods often struggle with the high-dimensional, heterogeneous nature of healthcare data. Recent work demonstrates the potential of LLMs for **contextual phenotyping** by leveraging their ability to understand and process complex clinical, demographic, and socioeconomic data [1](https://arxiv.org/pdf/2505.09805v1). By embedding a clustering objective into the LLM, the model can generate embeddings that facilitate the identification of patient subgroups with distinct profiles. This approach, exemplified by the use of models like Stella-En-400M-V5 and LLAMA 3.1 8B on pediatric sepsis data, outperformed classical techniques by capturing richer contextual information, proving valuable for targeted patient selection and resource optimization, particularly in resource-limited settings [1](https://arxiv.org/pdf/2505.09805v1).

However, the "black-box" nature of transformer models in this context can hinder clinical transparency and acceptance, necessitating further work on interpretability [1](https://arxiv.org/pdf/2505.09805v1). This challenge is actively being addressed by advancements in multimodal AI, which integrate diverse data types (e.g., images, time-series, text) for more comprehensive patient understanding and explainable outputs. Frameworks like MINT enhance LLM performance for tasks such as rare disease prediction and tissue classification by transferring knowledge from multimodal biomedical data to unimodal LLMs through preference optimization [2](https://arxiv.org/pdf/2505.05736v1). Similarly, QoQ-Med and MMedAgent-RL demonstrate the capability of multimodal LLMs to integrate varied clinical data for improved diagnostic accuracy and reasoning [3](https://arxiv.org/pdf/2506.00711v1), [4](https://arxiv.org/pdf/2506.00555v1). QoQ-Med, for instance, jointly reasons across medical images, time-series signals, and text reports, providing interpretability through salient region highlighting [3](https://arxiv.org/pdf/2506.00711v1). MMedAgent-RL, a multi-agent system simulating clinical workflows, shows promise in enhancing diagnostic precision through reinforcement learning, although it relies on proprietary models and specific prompt templates [4](https://arxiv.org/pdf/2506.00555v1). The Articulate Medical Intelligence Explorer (AMIE) further advances conversational diagnostic AI by integrating multimodal reasoning (e.g., skin photos, ECGs, clinical documents) for improved diagnostic accuracy compared to primary care physicians in simulated consultations [5](https://arxiv.org/pdf/2505.04653v1). These multimodal systems, while powerful, often face limitations in zero-shot generalization, explainability, and real-world clinical validation [2](https://arxiv.org/pdf/2505.05736v1), [4](https://arxiv.org/pdf/2506.00555v1), [3](https://arxiv.org/pdf/2506.00711v1), [5](https://arxiv.org/pdf/2505.04653v1).

## Automating Patient-to-Trial Matching

Patient recruitment remains a significant bottleneck in clinical trials. Automated solutions, such as **TrialMatchAI**, offer a promising approach by streamlining the patient-to-trial matching process [6](https://arxiv.org/pdf/2505.08508v1). This AI-powered recommendation system processes heterogeneous clinical data, including structured records and unstructured physician notes, utilizing fine-tuned, open-source LLMs within a retrieval-augmented generation (RAG) framework. The system normalizes biomedical entities, retrieves relevant trials using a hybrid search strategy, and performs criterion-level eligibility assessments via Chain-of-Thought (CoT) reasoning, delivering explainable outputs with traceable decision rationales. This significantly enhances the identification of suitable trials, especially biomarker-driven ones, improving efficiency and interpretability for expedited trial completion and patient access [6](https://arxiv.org/pdf/2505.08508v1).

However, TrialMatchAI, like other LLM-based systems, is susceptible to confabulations and misclassifications, and its accuracy can be impacted by incomplete patient records [6](https://arxiv.org/pdf/2505.08508v1). The reliance on the Phenopackets data format and the computational cost associated with LLMs pose practical barriers to direct integration into existing clinical workflows [6](https://arxiv.org/pdf/2505.08508v1). The broader field of medical LLMs is rapidly advancing, with benchmarks like BRIDGE evaluating their performance across diverse real-world clinical text tasks and languages, showing that open-source models can achieve performance comparable to proprietary ones. The use of LLMs for automated patient record linkage also highlights their potential to integrate fragmented healthcare data, although hybrid rule-based approaches may still offer higher efficiency for blocking. The development of smaller, more resource-efficient language models (SLMs) is also a promising avenue for scalable and clinically viable solutions in resource-constrained environments [41](https://www.semanticscholar.org/paper/d0e6b0a43edec2424005ee900c6d657597bd7d16).

## Estimating Individual Treatment Effects and Optimizing Treatment Strategies

Tailoring treatments to individual patient characteristics based on estimated treatment effects is central to precision medicine and critical for optimizing clinical trials. The **Double-NN method** offers a robust approach for estimating Individual Treatment Effects (ITEs) and quantifying their uncertainty, especially beneficial for personalized treatment strategies in clinical trials [7](https://arxiv.org/pdf/2505.01995v1). By employing deep neural networks to model treatment and control effect functions within the framework of extended fiducial inference, this method captures complex, nonlinear relationships and identifies patient subgroups with varying responses, improving patient stratification and treatment effect variability assessment [7](https://arxiv.org/pdf/2505.01995v1). Its superior performance in prediction interval coverage and length over methods like conformal quantile regression (CQR) indicates more reliable and precise ITE estimations. However, its generalizability requires testing on a broader range of clinical trial datasets, and computational cost and hyperparameter tuning remain considerations [7](https://arxiv.org/pdf/2505.01995v1).

Complementing ITE estimation, identifying predictive biomarkers is crucial for optimizing treatment outcomes. A novel methodology leverages **SHAP values** within Causal Average Treatment Effect (CATE) modeling to pinpoint such biomarkers, particularly in complex, multi-stage CATE strategies [8](https://arxiv.org/pdf/2505.01145v1). This approach offers practical guidance on interpreting complex machine learning models, facilitating the identification of patient subgroups that benefit most from specific treatments, thus optimizing trial design and patient selection [8](https://arxiv.org/pdf/2505.01145v1). Limitations include computational complexity, reliance on the accuracy of the underlying CATE models, and the need for further validation beyond simulations [8](https://arxiv.org/pdf/2505.01145v1).

For scenarios with a multitude of treatment options, the **calibration-weighted treatment fusion** method addresses data sparsity and covariate imbalance across treatment groups by merging similar treatments [9](https://arxiv.org/pdf/2505.08092v2). This enables the application of advanced ITR learning techniques, leading to more robust and flexible treatment recommendations and optimized treatment assignment in complex clinical trial settings. While consistent and doubly robust, this method may face instability with very few observations per treatment arm and its real-world performance compared to current clinical techniques warrants further investigation [9](https://arxiv.org/pdf/2505.08092v2).

Furthermore, learning treatment allocation policies in clinical trials necessitates balancing patient benefit with the risk of adverse effects. A **certifiable learning method** is proposed to control "treatment risk" (the proportion of patients receiving treatment without benefit) while minimizing overall population risk [10](https://arxiv.org/pdf/2505.08378v1). This method is crucial for ethical trial conduct, ensuring a degree of safety by limiting unnecessary harm, and is particularly pertinent for personalized medicine by providing probabilistic guarantees even with incomplete data [10](https://arxiv.org/pdf/2505.08378v1). Its effectiveness, however, depends on accurate estimation of miscalibration degrees and its current focus on binary outcomes and specific policy classes limits broader applicability [10](https://arxiv.org/pdf/2505.08378v1).

To address the high cost of data labeling in treatment effect estimation, particularly for outcomes requiring expensive procedures, the **FCCM (Factual and Counterfactual Covering Maximization)** method employs an active learning strategy [11](https://arxiv.org/pdf/2505.05242v1). This novel algorithm adaptively chooses which patients to include for labeling, aiming to reduce the number of patients required while maintaining accuracy. This can lead to more cost-effective trials, faster results, and quicker access to new therapies by optimizing resource use and refining treatment efficacy with limited data [11](https://arxiv.org/pdf/2505.05242v1). Key assumptions, such as strong ignorability and partially overlapping distributions, must hold true in real-world data for optimal performance [11](https://arxiv.org/pdf/2505.05242v1).

## Addressing Key Challenges for Clinical Integration

Despite these significant advancements, the integration of AI into clinical trial design and patient selection faces common challenges. A pervasive issue is the reliance on synthetic or limited real-world datasets for validation, which may not fully capture the complexity and nuances of diverse clinical populations and disease presentations. This highlights the ongoing need for robust validation on a broader range of complex, noisy, real-world clinical trial data.

Furthermore, the "black-box" nature of many deep learning models, particularly LLMs, remains a barrier to clinical transparency and acceptance. While progress is being made in explainable AI (XAI) and uncertainty quantification to foster trust, rigorous validation of these interpretability features in real clinical settings is crucial. Computational requirements, data privacy, security, and the need for data standardization (e.g., conversion to Phenopackets) present practical deployment challenges that must be addressed through careful model optimization, federated learning approaches, and adherence to regulatory frameworks [6](https://arxiv.org/pdf/2505.08508v1), [41](https://www.semanticscholar.org/paper/d0e6b0a43edec2424005ee900c6d657597bd7d16). The development of smaller, more resource-efficient language models (SLMs) is also a promising avenue for scalable and clinically viable solutions in resource-constrained environments [41](https://www.semanticscholar.org/paper/d0e6b0a43edec2424005ee900c6d657597bd7d16).

Ultimately, the successful translation of these AI innovations into clinical practice requires a multidisciplinary effort, integrating machine learning expertise with deep domain knowledge in clinical science, regulatory affairs, and medical ethics to ensure safe, equitable, and effective patient care.

# Advancements in Secure Data Management and Synthetic Data Generation

The rapid digitization of healthcare presents unprecedented opportunities for AI-driven clinical research; however, these opportunities are often constrained by stringent data privacy regulations, security concerns, and data scarcity. To mitigate these challenges, innovative AI solutions are emerging, broadly categorized into high-fidelity synthetic data generation and privacy-preserving federated learning, both enabling broader access to diverse datasets for research, algorithm development, and trial design optimization.

## High-Fidelity Synthetic Data Generation

Synthetic data generation offers a compelling approach to overcome privacy concerns and data accessibility limitations by mimicking the statistical and structural properties of real-world data without exposing sensitive information [12](https://arxiv.org/pdf/2505.05019v1). A key challenge lies in ensuring that synthetic datasets maintain high fidelity, utility, and adherence to domain-specific constraints. One significant advancement in this area demonstrates that hyperparameter optimization (HPO) substantially improves the quality of synthetic data, particularly when employing compound metric optimization strategies rather than single-metric approaches [12](https://arxiv.org/pdf/2505.05019v1). For instance, models such as TVAE, CTGAN, and CTAB-GAN+ showed improvements of up to 60%, 39%, and 38% respectively. However, HPO alone is insufficient to guarantee clinical validity, underscoring the critical necessity of integrating explicit domain knowledge and robust preprocessing/postprocessing techniques to address violations of fundamental clinical constraints [12](https://arxiv.org/pdf/2505.05019v1). The limitations of this approach include its reliance on predefined hyperparameter spaces, computational costs for complex architectures like GReaT, and a focus on limited evaluation metrics and clinical constraints.

Beyond tabular data, advancements extend to synthetic medical imaging. The Cardiac Phenotype-Guided CMR Generation (CPGG) framework exemplifies this by synthesizing high-quality Cardiac Magnetic Resonance (CMR) data conditioned on specific cardiac phenotypes [13](https://arxiv.org/pdf/2505.03426v1). This two-stage framework first trains a generative model using cardiac phenotypes and then employs a masked autoregressive diffusion model to generate high-fidelity CMR cine sequences, capturing both structural and functional features. This method addresses the scarcity of large-scale, high-quality CMR datasets, which often impedes AI model development for automated diagnosis, risk stratification, and treatment response prediction in clinical trials [13](https://arxiv.org/pdf/2505.03426v1). While CPGG can enhance AI model performance and accelerate trial efficiency, its effectiveness is inherently tied to the accuracy of the conditioning phenotypes, and it faces challenges related to generalizability across diverse imaging protocols and substantial computational costs. Ethical considerations regarding bias and misuse of synthetic data also warrant further investigation, a point often overlooked in current studies [13](https://arxiv.org/pdf/2505.03426v1).

## Privacy-Preserving Federated Learning

Federated Learning (FL) is a transformative paradigm enabling collaborative model training across multiple institutions without centralizing sensitive patient data. This decentralized approach is particularly attractive in healthcare due to regulatory frameworks like HIPAA (Health Insurance Portability and Accountability Act) and GDPR (General Data Protection Regulation) [14](https://arxiv.org/pdf/2505.08085v1).

Addressing algorithmic bias and subgroup imbalance, which are exacerbated by heterogeneous and non-IID (non-independent and identically distributed) data distributions inherent in FL settings, is crucial [15](https://arxiv.org/pdf/2505.09295v1). The FedIDA framework proposes a solution by combining fairness-aware regularization with group-conditional oversampling, supporting multiple sensitive attributes and maintaining competitive predictive performance while improving fairness metrics like DPD and DPR [15](https://arxiv.org/pdf/2505.09295v1). This framework allows for more inclusive and representative models, though its reliance on predefined sensitive attributes and limitations on convergence behavior based on the underlying FL algorithm remain challenges.

For causal inference in distributed healthcare, Federated Causal Inference (FCI) methods allow for the estimation of treatment effects across multiple data sources without sharing individual-level data [16](https://arxiv.org/pdf/2505.02238v1). This is vital for generating real-world evidence and improving clinical trials by evaluating treatments across diverse patient populations while protecting sensitive data. The theoretical analysis of FCI methods, including weight-based strategies and optimization-based frameworks, reveals that FedProx-style regularization achieves near-optimal bias-variance trade-offs [16](https://arxiv.org/pdf/2505.02238v1). Practical implementation, scalability, and computational costs remain considerations, alongside the need for standardized federated datasets to ensure widespread adoption.

Federated learning is also being extended to various model types beyond gradient-based approaches. A notable advancement introduces a federated learning framework for Random Forest classifiers, allowing multiple institutions to collaboratively train models on local data using PySyft for secure computation [14](https://arxiv.org/pdf/2505.08085v1). Random Forests are often favored in clinical settings for their interpretability, enhancing trust in decision-making processes. This framework maintains competitive predictive accuracy, typically within a 9% margin of centralized methods, demonstrating that the benefits of improved data access and collaboration often outweigh minor accuracy trade-offs [14](https://arxiv.org/pdf/2505.08085v1). However, a degree of accuracy degradation compared to centralized methods is inherent, and further validation on diverse clinical datasets is needed.

To enhance privacy, security, and efficiency, the BFEL framework integrates blockchain technology with advanced federated learning techniques like FedCurv [17](https://arxiv.org/pdf/2506.00416v1). FedCurv incorporates second-order information via the Fisher Information Matrix, which is critical for handling heterogeneous and non-IID data common in clinical trials, thus improving model convergence and reducing communication rounds [17](https://arxiv.org/pdf/2506.00416v1). Blockchain ensures secure model aggregation and auditability, fostering trust in the results, which is essential for clinical validation. Despite these benefits, challenges include computational overhead, increased implementation complexity, scalability concerns for massive datasets, and the need for rigorous regulatory compliance with standards like HIPAA and GDPR [17](https://arxiv.org/pdf/2506.00416v1). The efficacy of such frameworks in directly improving clinical outcomes (e.g., patient recruitment, outcome prediction) remains an area for further empirical validation.

Overall, these advancements in synthetic data generation and federated learning represent a significant leap towards secure, scalable, and privacy-preserving AI in clinical research. While both paradigms offer distinct advantages in addressing data access and privacy, ongoing research continues to refine their methodologies, tackle computational and ethical challenges, and bridge the gap between theoretical promise and real-world clinical implementation.

# Causal AI for Robust Treatment Effect Estimation and Safety Monitoring

Advancing the accuracy and reliability of clinical trials requires sophisticated methodologies for causal inference, particularly in complex scenarios involving dynamic treatment regimens, patient non-adherence, and latent confounding. Artificial intelligence (AI), especially in its application to causal inference, is proving instrumental in addressing these challenges, while also enhancing drug safety monitoring through automated adverse event detection and summarization.

## Enhancing Robust Treatment Effect Estimation in Complex Settings

Traditional causal inference methods often struggle with the intricacies of real-world clinical data, such as time-varying treatments, non-adherence, and unmeasured confounders. Modern AI approaches are developing robust solutions.

For **time-varying treatments and confounders**, which are prevalent in adaptive clinical practice, methods are needed to account for treatment-confounder feedback loops. **TV-SurvCaus** offers a novel framework that synergizes representation balancing with sequential modeling to estimate causal effects of time-varying treatments on survival outcomes [18](https://arxiv.org/pdf/2505.01785v1). By integrating recurrent neural networks with an explicit mechanism for balancing time-dependent representations across treatment sequences, TV-SurvCaus addresses selection bias and allows for more reliable estimation of individualized treatment effects, demonstrated on datasets like MIMIC-III. This is particularly crucial for developing personalized treatment strategies that adapt over time. However, like many causal inference techniques, TV-SurvCaus relies on strong assumptions such as sequential exchangeability, positivity, and no unmeasured confounding, which may be difficult to fully satisfy in practice. Its deep learning architecture also introduces interpretability challenges and can be computationally intensive, particularly for large datasets. Similarly, **Causal Analysis for Survival Trajectories (CAST)** models treatment effects as continuous functions of time, aiming to capture dynamic changes that fixed-time-point analyses miss, as demonstrated in chemotherapy and radiotherapy on head and neck squamous cell carcinoma. The broader concept of using continuous-time marked point process weights is also explored for long-term treatment effects in observational data.

Further extending capabilities to address **unmeasured confounders** in sequential treatment effect estimation, the **Decomposing Sequential Instrumental Variable framework for CounterFactual Regression (DSIV-CFR)** proposes a novel approach [19](https://arxiv.org/pdf/2505.09113v1). This framework leverages transformer architectures to capture long-term temporal dependencies in patient data and integrates instrumental variables and negative controls to mitigate bias from unmeasured confounders. This capability is vital for informing personalized treatment strategies and could facilitate adaptive trial designs where optimal treatments for different patient subgroups can be dynamically determined. However, DSIV-CFR's effectiveness hinges on assumptions regarding negative controls and the time-invariance of relationships, which might not always hold in complex biological systems. The computational complexity of transformer-based models also presents a practical barrier for large-scale clinical data analysis.

**Non-adherence** to assigned treatments is another significant hurdle in clinical trials and observational studies, biasing treatment effect estimates. The **Conditional Front-door Adjustment (CFD)**, particularly when implemented with the proposed LobsterNet neural network, offers a method to more precisely estimate heterogeneous treatment assignment effects under non-adherence [20](https://arxiv.org/pdf/2505.05677v1). This approach can yield lower-variance estimates compared to standard backdoor adjustment (SBD), especially when true treatment effects are subtle. LobsterNet's multi-task learning for nuisance parameters also offers a practical and scalable solution. Despite these advantages, CFD's applicability is limited by its current focus on binary treatments and its reliance on the availability and reliability of adherence data. Furthermore, it does not explicitly address unmeasured confounding, which remains a pervasive challenge in observational data.

Beyond these specific challenges, several AI-driven advancements address **broader causal inference issues**:
*   **Confounding and Selection Bias**: Doubly robust methods continue to be a cornerstone for robust estimation, combining strengths of different modeling approaches and addressing issues like propensity ambiguity and statistical instability through adversarial losses or density ratio-free techniques.
*   **Adaptive Trial Design and Efficiency**: Cluster-based multi-armed bandit (MAB) algorithms are proposed to efficiently learn total treatment effects in networked environments, like patient communication networks, while minimizing exposure to less effective treatments [21](https://arxiv.org/pdf/2505.04200v1). This adaptive learning paradigm can optimize trial efficiency and personalize interventions.
*   **Data Heterogeneity and Privacy**: For multi-site clinical collaborations, federated causal inference methods are emerging to enable treatment effect estimation without sharing individual-level data, addressing privacy concerns and data heterogeneity challenges across institutions.
*   **Complex Outcome Modeling**: Beyond single-outcome predictions, diffusion-based methods like DIME are being developed to learn the joint distribution of multiple, interdependent treatment outcomes (e.g., primary endpoints, adverse events), providing a more comprehensive view for optimal treatment decisions with uncertainty quantification.
*   **Continuous-Time Biomarker Dynamics**: Analyzing the continuous-time evolution of biomarker distributions, such as glucose levels in diabetes trials, is crucial for understanding treatment effects. A novel probabilistic model based on Gaussian mixtures and Neural Ordinary Differential Equations (Neural ODEs) provides an interpretable and computationally efficient way to capture subtle temporal shifts in these distributions [22](https://arxiv.org/pdf/2505.08698v1). This approach allows for rigorous comparison of treatment and control groups and offers new insights into biomarker dynamics that traditional techniques might miss.

## AI in Drug Safety Monitoring and Adverse Drug Event Identification

Comprehensive drug safety monitoring is an indispensable component of clinical trials and post-market surveillance. AI is significantly enhancing the efficiency and accuracy of identifying and summarizing adverse drug effects (ADEs).

**Causal Knowledge Graphs (CKGs)** represent a significant advancement for automated adverse drug reaction (ADR) identification and hypothesis generation [23](https://arxiv.org/pdf/2505.06949v1). By extending traditional knowledge graphs with formal causal semantics, CKGs integrate vast amounts of biomedical background knowledge, enabling robust causal reasoning. The **Drug-Disease CKG (DD-CKG)**, for instance, allows for large-scale mediation analysis to discover both known and previously undocumented candidate adverse drug effects, adjusting for confounders inferred from the graph structure. This structured approach automates hypothesis generation and can significantly improve pharmacovigilance. However, the accuracy of CKG-derived insights is highly dependent on the quality and completeness of the underlying data sources and the challenges of data standardization across different terminologies. The inherent reliance on observational data also introduces concerns about unmeasured confounding that cannot be fully mitigated by graph-based deconfounding.

To manage the ever-increasing volume of patient-reported ADEs, automated summarization is becoming critical. The **GASCADE framework** addresses this by providing a pipeline for grouped summarization of adverse drug events from patient reports [24](https://arxiv.org/pdf/2505.04284v1). Utilizing Large Language Models (LLMs) for information extraction and an encoder-decoder T5 model enhanced with Direct Preference Optimization (DPO) for summarization, GASCADE automates the consolidation of safety data. This capability can accelerate the analysis of safety signals, allowing for earlier detection of potential drug risks during trials and informing real-time decisions on dose adjustments or patient management. While promising, the generalizability of GASCADE is currently limited by its primary focus on cancer drugs, and the quality of generated summaries remains dependent on the synthetic preference data used for DPO and the inherent limitations of LLMs in accurately processing potentially biased or incomplete patient-reported information.

In conclusion, causal AI is poised to revolutionize clinical trials by providing more robust and reliable methods for estimating treatment effects under complex real-world conditions, while simultaneously strengthening drug safety monitoring. The development of sophisticated causal inference frameworks that account for time-varying treatments, non-adherence, and unmeasured confounders, alongside AI-driven tools for automated ADE identification and summarization, are critical steps toward more efficient, personalized, and safer therapeutic development. Continued research must focus on addressing the underlying assumptions, computational scalability, and interpretability challenges to facilitate their widespread adoption in clinical practice.

# LLM-Powered Automation for Clinical Protocol Design and Knowledge Synthesis

The exponential growth of medical literature and complex clinical data presents a formidable challenge for researchers and clinicians seeking to extract meaningful insights, design robust clinical trials, and synthesize evidence efficiently. Large Language Models (LLMs) are emerging as transformative tools to streamline these processes, offering capabilities ranging from automated literature review and evidence extraction to generating high-quality medical text and ensuring factual accuracy.

## Streamlining Evidence Synthesis and Literature Review

One of the most time-consuming aspects of clinical research, including the foundational steps of clinical trial design and systematic reviews, is the exhaustive process of evidence synthesis. LLMs are proving instrumental in automating and enhancing this process. For instance, the **URCA (Uniform Retrieval Clustered Augmentation) framework** addresses the critical challenge of extracting scientific evidence from biomedical studies, especially when dealing with conflicting findings [25](https://arxiv.org/pdf/2505.06186v1). By leveraging the **CochraneForest dataset**, designed from Cochrane systematic reviews, URCA demonstrates superior performance in document-level scientific evidence extraction, thereby reducing the time and cost associated with manual systematic reviews. However, the absence of rationale annotations in the CochraneForest dataset limits detailed error analysis, hindering a deeper understanding of model failures [25](https://arxiv.org/pdf/2505.06186v1).

Furthermore, the construction of effective Boolean queries is paramount for retrieving relevant literature in systematic reviews. Traditional methods are laborious, often requiring specialized librarians. Research indicates that LLMs can automate and improve this task, with findings highlighting that **model selection and prompt design** are key drivers for generating high-quality queries that achieve higher recall [26](https://arxiv.org/pdf/2505.07155v2). This capability can significantly accelerate the literature review phase in clinical trial planning. Frameworks like PROMPTHEUS offer an AI-driven pipeline to automate systematic literature reviews, encompassing systematic searches, data extraction, and summarization, thereby enhancing efficiency and precision in synthesizing comprehensive evidence [27](https://www.semanticscholar.org/paper/b81dcd32fbf9bcef7a5314cf94466251dd3b7d3e). Similarly, Valsci provides an open-source utility for large-batch scientific claim verification by integrating retrieval-augmented generation (RAG) with structured bibliometric scoring, reducing hallucination rates compared to standalone LLMs [28](https://www.semanticscholar.org/paper/13e079da1dba19509dfd1fd05440b1a52666603a).

## Enhancing Medical Text Generation and Insight Refinement

Beyond extraction, LLMs are also being developed to generate structured medical text and synthesize research insights. The **FRAME (Feedback-Refined Agent Methodology)** offers a novel approach to enhance automated medical paper generation [29](https://arxiv.org/pdf/2505.04649v1). FRAME employs a tripartite architecture consisting of Generator, Evaluator, and Reflector agents that iteratively refine content quality. This agentic feedback loop leads to significant improvements in generating high-quality medical research papers, particularly in synthesizing future research directions, which can accelerate hypothesis formulation and trial design. Acknowledged limitations include dependence on the quality of initial retrieval and restriction to offline datasets, meaning it cannot dynamically incorporate the latest research [29](https://arxiv.org/pdf/2505.04649v1).

## Mitigating Hallucinations and Ensuring Factual Accuracy

A critical concern in deploying LLMs in high-stakes domains like clinical research is the potential for "hallucinations"—the generation of factually incorrect or unsupported information. These can pose significant risks to patient safety and trial integrity [30](https://arxiv.org/pdf/2506.00448v1). To address this, new methods are emerging for **fact-controlled diagnosis of hallucinations in medical text summarization** [30](https://arxiv.org/pdf/2506.00448v1). By constructing datasets that systematically induce or organically capture hallucinations, researchers are developing specialized metrics to detect and quantify these errors, offering transparency and improving the trustworthiness of AI-driven tools.

**Retrieval-Augmented Generation (RAG)** systems are a key innovation to mitigate hallucinations by grounding LLM outputs in verifiable external sources. Research demonstrates that optimizing RAG hyperparameters, such as vector store choice, chunking policies, and re-ranking, can significantly improve retrieval accuracy and answer correctness, crucial for applications like clinical decision support [31](https://arxiv.org/pdf/2505.08445v1). For instance, Faiss vector stores tend to yield higher precision than Chroma, while naive fixed-length chunking offers a good balance of accuracy and speed. While re-ranking can modestly improve quality, its five-fold increase in runtime must be weighed against latency constraints [31](https://arxiv.org/pdf/2505.08445v1). Various RAG advancements further enhance its application: strategies like BriefContext combat the "lost-in-the-middle" problem in long medical contexts [32](https://www.semanticscholar.org/paper/8bbfa19b5ef55c22b773cee948a664f0b514e0a0).

The integration of **Knowledge Graphs (KGs)** further strengthens LLMs' factual precision. The **SENATOR framework** proposes a Structural Entropy-guided Knowledge Navigator that addresses intrinsic knowledge deficiencies in LLMs by identifying "blind spots" and generating targeted synthetic data for fine-tuning [33](https://arxiv.org/pdf/2505.07184v1). This approach, guided by structural entropy and Monte Carlo Tree Search, can optimize LLM training with domain-specific knowledge relevant to clinical trial tasks, such as patient selection criteria. However, its effectiveness heavily relies on the quality and completeness of the underlying knowledge graph [33](https://arxiv.org/pdf/2505.07184v1). Other methods, like ConTextual, combine context-preserving token filtering with KGs to improve linguistic coherence and clinical fidelity in summarization [34](https://www.semanticscholar.org/paper/36bf667b489fc59ef684913a5f535f4949ca7584). Investigations into GraphRAG also highlight how KGs can improve interpretability and reliability by linking answers to verifiable graph paths and textbook passages [35](https://www.semanticscholar.org/paper/573721af3692834841c3e82303a3bfabb98423b9). Query refinement techniques combined with KGs have drastically reduced hallucinations and improved accuracy in medical QA systems by enforcing syntactic, semantic, and logical integrity of queries against KG schemas [36](https://www.semanticscholar.org/paper/fab0506cd76a8c4308f3643d6af8a9e769f19af7).

Despite these advancements, challenges remain in synthetic data generation, where hallucinations and factual inconsistencies can persist, underscoring the need for domain-specific evaluation metrics and hybrid techniques combining retrieval-based grounding with fine-tuning [37](https://www.semanticscholar.org/paper/9efdd09bb8c967052f7e035f45f4e41fad79c7d0).

## The Role of Open-Source LLMs and Comprehensive Evaluation

The development of **open-source LLMs tailored for healthcare**, such as the **Aloe Family models**, is crucial for fostering transparency, reproducibility, and community-driven improvement [38](https://arxiv.org/pdf/2505.04388v1). These models, built on strong base architectures and optimized with techniques like Direct Preference Optimization (DPO) and RAG, offer competitive performance across healthcare benchmarks, facilitating customizability for specific clinical trial tasks while emphasizing ethical considerations.

The responsible deployment of LLMs in healthcare necessitates robust and comprehensive evaluation. Current benchmarks, often based on medical licensing exams, may not fully capture the complexities of real-world clinical practice. These efforts, alongside surveys on trustworthiness in medical QA and RAG evaluation [39](https://www.semanticscholar.org/paper/79e57387a664a5d7b128b2790a8f38f827e09124), highlight the ongoing need for scalable, multi-dimensional metrics to ensure safe, reliable, and transparent LLM deployment. Emerging Small Language Models (SLMs) also present a promising avenue for resource-efficient healthcare applications, offering improved reasoning capabilities through specialized training on medical textbooks [40](https://www.semanticscholar.org/paper/7445f3d7a16d992029585e93704ec44f0e99e43e), [41](https://www.semanticscholar.org/paper/d0e6b0a43edec2424005ee900c6d657597bd7d16).

## Challenges and Future Directions

Despite the significant advancements, several limitations and challenges must be addressed for the widespread and reliable adoption of LLMs in clinical protocol design and knowledge synthesis. These include:
*   **Generalizability and Data Biases:** The reliance on specific datasets limits the generalizability of models to the diverse and complex language found in real-world clinical documents [30](https://arxiv.org/pdf/2506.00448v1), [31](https://arxiv.org/pdf/2505.08445v1). LLMs may also inherit biases present in their training data, potentially affecting clinical outcomes or interpretations [38](https://arxiv.org/pdf/2505.04388v1).
*   **Computational Cost and Real-time Processing:** Some LLM-based evaluation and generation methods can be computationally expensive, hindering real-time application in resource-constrained clinical settings [30](https://arxiv.org/pdf/2506.00448v1).
*   **Lack of Interpretability and Rationale:** The absence of rationale annotations in datasets or explicit reasoning pathways in models makes error analysis and understanding model decisions challenging, which is crucial for high-stakes medical applications [25](https://arxiv.org/pdf/2505.06186v1).
*   **Integration and Validation:** Seamless integration into existing clinical workflows and adherence to stringent regulatory requirements remain significant hurdles for LLM deployment [38](https://arxiv.org/pdf/2505.04388v1).
*   **Maintaining Factual Consistency and Trustworthiness:** While RAG and KG integration mitigate hallucinations, the persistent challenge of ensuring absolute factual accuracy and preventing the propagation of misinformation remains paramount, especially with dynamic knowledge sources [37](https://www.semanticscholar.org/paper/9efdd09bb8c967052f7e035f45f4e41fad79c7d0), [36](https://www.semanticscholar.org/paper/fab0506cd76a8c4308f3643d6af8a9e769f19af7).

The future trajectory of LLMs in clinical protocol design and knowledge synthesis will likely involve continued refinement of RAG and KG-based approaches, the development of more robust evaluation frameworks, and the exploration of multi-agent systems for enhanced reasoning and verification. Ultimately, human oversight and validation will remain indispensable to ensure the safety, efficacy, and ethical deployment of these powerful AI tools in healthcare.

# AI in Real-time Patient Monitoring for Enhanced Trial Execution

The efficiency and safety of clinical trial execution are profoundly influenced by the ability to monitor patients continuously and detect adverse events or deterioration promptly. Traditional monitoring systems often rely on periodic assessments, which can delay interventions and compromise patient outcomes, particularly in critical care settings like Intensive Care Units (ICUs) where conditions can change rapidly [42](https://www.semanticscholar.org/paper/c84ef7adb1d027762e941a9a8f2f6caec6366490). Artificial Intelligence (AI) and the integration of real-time data from wearable devices are poised to revolutionize this landscape, enabling proactive clinical decision-making and enhancing the reliability of trial data.

A significant advancement in this domain is the proposed **TARL** model, an innovative machine learning framework designed for the early detection of patient deterioration using real-time heart rate data from wearable devices [43](https://arxiv.org/pdf/2505.01305v1). TARL addresses key challenges in processing diverse and often incomplete wearable data by employing a sophisticated methodology. It leverages **shapelet analysis** to identify representative subsequences or patterns within heart rate time series, which are indicative of illness progression. These patterns are then modeled using a **shapelet-transition knowledge graph**, capturing their dynamic relationships and potential future changes. To enhance robustness, TARL incorporates a **transition-aware knowledge embedding** to reinforce relationships among shapelets and quantify the impact of missing values, a common issue with real-world wearable data. This comprehensive representation allows the model to predict future heart rate trends and aid in early illness detection.

The clinical utility of TARL lies in its ability to detect patient deterioration approximately 6 hours in advance, a critical "golden window" for many therapeutic interventions [43](https://arxiv.org/pdf/2505.01305v1). This proactive capability offers substantial benefits for clinical trials, enabling earlier intervention in adverse events, potentially reducing trial durations, and enhancing overall patient safety by swiftly identifying deviations from expected patient trajectories. Furthermore, the model's emphasis on **explainability** is crucial for clinical adoption, providing transparency into its predictions and fostering trust among healthcare professionals [43](https://arxiv.org/pdf/2505.01305v1).

The integration of AI with wearable technology for continuous patient monitoring is a rapidly evolving field, with numerous related efforts amplifying the potential of such systems. Wearable devices, from smartwatches to specialized sensors, are increasingly recognized for their ability to provide continuous, non-invasive physiological data, including heart rate, stress levels, activity, and sleep patterns [44](https://www.semanticscholar.org/paper/59ea60ef5fb24d99ece1d1d77c5e1b74b534946e), [45](https://www.semanticscholar.org/paper/f921dae76cfdf6155f685fb355208af786292fb4), [46](https://www.semanticscholar.org/paper/dce80322afb5ca2bc91de58b4ba049cbf2c800fa), [47](https://www.semanticscholar.org/paper/e12e777b87213cc001119eb078eff21ff0b4583f), [48](https://www.semanticscholar.org/paper/cedad978a16f6e7a714e1a9edf88ef0fa49e99a4), [49](https://www.semanticscholar.org/paper/5e01ec700d8a6bc66926c32536278ea24a3f4a6c). These devices form the data acquisition layer for AI pipelines designed for real-time health event detection, such as fall detection or cardiac arrhythmia identification [50](https://www.semanticscholar.org/paper/3a3479d7bbce357bb715d3f431ec6bd2f448580a). Studies have shown promising reliability for continuous vital sign monitoring in acute hospital settings, paving the way for their broader clinical integration [51](https://www.semanticscholar.org/paper/7bf89fc7c68bbe44680dc167b12f587dc04de185).

While TARL primarily focuses on heart rate, a significant trend in AI-driven health monitoring involves the integration of **multimodal data** to create more comprehensive patient representations. Research demonstrates how combining electronic health records (EHRs), lab tests, medical images, clinical notes, and various wearable sensor streams can lead to more discriminative patient insights and improved predictive accuracy for conditions ranging from sepsis mortality [52](https://www.semanticscholar.org/paper/b847ce14966bdb9af77501f0850f45b4411f85e0) to chronic disease risks [53](https://www.semanticscholar.org/paper/0b58e33e5512543ac6fb3c30644ae8b3a54d76c0), [54](https://www.semanticscholar.org/paper/0a5e758c6f23306494bbb4fca16441469a451935), [55](https://www.semanticscholar.org/paper/9b944dacca2a85a6ed715a62e2a4b139f841b6db). This multimodal approach helps overcome limitations of single-modality data and addresses issues like missing values and inter-modality relationships. For instance, models are being developed to predict chronic respiratory diseases by integrating EHRs, genomic data, environmental factors, and wearable data [56](https://arxiv.org/abs/10.54660/.ijfmr.2023.4.1.1084-1094). Similarly, prediction of nocturnal hypoglycemia in children with Type 1 Diabetes has been improved by incorporating physiological data beyond glucose levels [57](https://www.semanticscholar.org/paper/3bd03ada8c56c8e948dbfc01fc39461048acdd22).

The demand for **Explainable AI (XAI)**, as highlighted by TARL's design, is a recurrent theme across the field. Clinicians require transparency to trust and adopt AI systems. This interpretability is crucial for making AI not just accurate but also actionable in healthcare settings.

Despite the transformative potential, several challenges persist for widespread adoption. These include concerns about **data privacy, algorithmic bias, system integration** with existing healthcare infrastructure, and the **generalizability** of models trained on single-center datasets [42](https://www.semanticscholar.org/paper/c84ef7adb1d027762e941a9a8f2f6caec6366490), [45](https://www.semanticscholar.org/paper/f921dae76cfdf6155f685fb355208af786292fb4), [58](https://www.semanticscholar.org/paper/d80607f5e0a19f89d84ec21e888b839621426b66). The need for robust validation, often against clinical gold standards, is paramount [51](https://www.semanticscholar.org/paper/7bf89fc7c68bbe44680dc167b12f587dc04de185). Innovative solutions like **federated learning** are emerging to address privacy by enabling collaborative model training without sharing raw patient data, while **edge computing** facilitates real-time processing on mobile and wearable devices, reducing latency and reliance on centralized servers [59](https://www.semanticscholar.org/paper/c5eb9a6643af5bd98292d3b690e70aed9234f049), [60](https://www.semanticscholar.org/paper/2f8956fea8ffe3f71c50f0a8dc192ad8af9d5496), [61](https://www.semanticscholar.org/paper/19e05c46bf3d30aadfb603599b511fba684dcd6a).

In conclusion, AI-driven real-time patient monitoring, exemplified by innovations like TARL, represents a significant leap forward in clinical trial execution. By enabling early detection of subtle physiological changes, these systems can facilitate timely interventions, improve patient safety, and enhance the reliability of trial data. The ongoing advancements in wearable technology, multimodal data fusion, and explainable AI, coupled with a focus on addressing practical deployment challenges, are collectively paving the way for a future where clinical trials are more efficient, safer, and ultimately more effective in bringing new therapies to patients.

# Ensuring Trustworthiness and Interpretability of AI in Clinical Trials

The integration of Artificial Intelligence (AI) into clinical trials promises transformative advancements, from optimizing patient recruitment to accelerating data analysis and enhancing diagnostic accuracy. However, the successful and safe deployment of AI in such safety-critical environments hinges on the trustworthiness and interpretability of these sophisticated models. This section explores key advancements in Uncertainty Quantification (UQ) and multimodal foundation models, alongside strategies for improving generalizability and explainability, all vital for fostering clinician trust and regulatory acceptance.

**Uncertainty Quantification for Reliable Clinical Decisions**

Machine learning models, particularly deep neural networks, often provide point predictions without indicating their confidence, which is problematic in high-stakes clinical settings. Uncertainty Quantification (UQ) addresses this by providing estimates of a model's confidence in its predictions, distinguishing between *aleatoric uncertainty* (inherent noise in data) and *epistemic uncertainty* (due to limited data or model knowledge) [62](https://arxiv.org/pdf/2505.02874v1). This distinction is crucial for understanding the reliability of AI-driven clinical decision support systems.

Lechuga López et al. offer a comprehensive survey of UQ methods in healthcare, proposing a framework for their integration across the entire machine learning pipeline: data processing, model training, and evaluation [62](https://arxiv.org/pdf/2505.02874v1). At the data preprocessing stage, UQ methods like pseudo-labeling strategies and normalizing flow ensembles enhance data quality and mitigate noise and domain shifts [62](https://arxiv.org/pdf/2505.02874v1). During model training, techniques such as Bayesian Neural Networks (BNNs), Evidential Deep Learning (EDL), and ensemble methods are employed to capture both aleatoric and epistemic uncertainties, thereby improving model robustness and reducing overfitting. For example, EDL has been applied to tasks like prostate cancer grading and general surgery segmentation to provide meaningful uncertainty estimates [62](https://arxiv.org/pdf/2505.02874v1). Post-hoc calibration methods, including test-time augmentation and Dirichlet-based models, are utilized during evaluation to refine predictive uncertainty, ensuring well-calibrated predictions crucial for preventing misleading outputs in clinical practice [62](https://arxiv.org/pdf/2505.02874v1).

The ability of UQ to flag uncertain predictions allows for selective deferral to human experts, optimizing clinical workflows and improving decision-making, especially in high-risk scenarios [62](https://arxiv.org/pdf/2505.02874v1). However, the real-world implementation of UQ models faces challenges, including the need for computationally efficient methods, standardized evaluation frameworks, and careful consideration of data heterogeneity and biases [62](https://arxiv.org/pdf/2505.02874v1). Regulatory bodies, such as the FDA (Food and Drug Administration), Health Canada, and WHO (World Health Organization), are increasingly emphasizing interpretability and reliability, making UQ an implicit, yet vital, component for future AI medical device approvals [62](https://arxiv.org/pdf/2505.02874v1).

**Multimodal Foundation Models and Enhanced Generalizability**

Clinical trials often involve diverse data modalities, including medical images (CT, MRI, X-ray), Electronic Health Records (EHRs), and genomic data. Integrating these disparate data sources for comprehensive clinical reasoning is a significant challenge. Liu et al. introduce BioVFM, a large-scale medical vision foundation model, and BioVFM-21M, a dataset comprising 21 million biomedical images across 10 modalities and 30 anatomical structures [63](https://arxiv.org/pdf/2505.09329v1). Their work demonstrates that scaling up model and data size, particularly data *diversity*, can improve performance and generalizability across various medical image analysis tasks, crucial for diagnostic accuracy and automation in clinical trials [63](https://arxiv.org/pdf/2505.09329v1).

Beyond image-centric models, the field is moving towards multimodal large language models (MLLMs) that integrate text with imaging or genomic data for holistic diagnostic capabilities. Frameworks like Infi-Med aim for resource-efficient medical MLLMs with enhanced multimodal reasoning. Similarly, an integrative AI framework leverages deep learning models, including CNNs for image analysis and attention-based recurrent architectures for sequential clinical data, utilizing feature-level fusion and decision-level ensemble strategies for simultaneous diagnosis of multiple diseases. Other works, such as OmniV-Med and SurgVLM, highlight the development of unified frameworks and large-scale datasets for universal visual understanding and surgical intelligence, respectively, handling diverse 2D/3D images and videos within a single architecture. The focus on `image-centric multi-annotation data` (IMAX) also aims to cultivate comprehensive image understanding aligned with clinical needs for multi-dimensional image interpretation. Such multimodal approaches are essential for clinical trials, where a holistic understanding of patient data is paramount for patient selection, outcome prediction, and treatment optimization.

However, the generalizability of these models under real-world conditions remains a concern. Medical images are susceptible to acquisition artifacts and noise, and models need to be robust to these distortions and domain shifts. Addressing data heterogeneity and biases, which often arise from underrepresentation of certain populations or systematic exclusions in data collection, is critical for dependable AI systems [62](https://arxiv.org/pdf/2505.02874v1). Strategies like self-supervised pretraining on domain-specific data can enhance robustness and generalization compared to relying solely on ImageNet transfer learning.

**Fostering Trust and Addressing Practical Challenges**

Interpretability is a cornerstone of clinician trust and is intertwined with UQ. By providing insights into *why* a model made a certain prediction and *how confident* it is, UQ methods enhance transparency. For instance, XMedGPT, a clinician-centric multi-modal AI assistant, integrates textual and visual interpretability and quantifies uncertainty through a reliability indexing mechanism, grounding referenced anatomical sites within medical images. Similarly, Grad-CAM visualizations provide clinicians with visual justification for AI-driven decisions in lung disease diagnosis. Understanding whether uncertainty stems from data noise, model specification issues, or training data limitations is critical for actionable insights [62](https://arxiv.org/pdf/2505.02874v1).

Practical deployment of AI in clinical trials is further constrained by computational costs, data privacy, and regulatory hurdles. Training large foundation models is resource-intensive [63](https://arxiv.org/pdf/2505.09329v1). Innovations addressing this include lightweight models (e.g., EfficientNetV2-S, small language models, and Infi-Med's resource-efficient approach), which balance effectiveness with operational constraints. Federated Learning (FL) emerges as a promising solution for multi-institutional collaborations, enabling robust training without sharing raw patient data, thus addressing privacy concerns and data accessibility issues [62](https://arxiv.org/pdf/2505.02874v1).

In conclusion, ensuring trustworthiness and interpretability of AI in clinical trials requires a multifaceted approach. Integrating UQ across the ML pipeline, developing sophisticated multimodal foundation models, enhancing generalizability through diverse and robust training, and prioritizing interpretability are critical steps. A structured roadmap for development, including standardized evaluation frameworks and addressing computational and ethical barriers, is essential to realize the full potential of AI in accelerating and improving clinical trial outcomes [62](https://arxiv.org/pdf/2505.02874v1). This necessitates continued interdisciplinary collaboration between AI researchers, clinicians, and policymakers to align technological advancements with real-world clinical needs and regulatory requirements.

## Spotlight: TrialMatchAI – Revolutionizing Patient-to-Trial Matching

The timely recruitment of eligible patients remains a critical bottleneck in clinical trials, impeding the advancement of new treatments, particularly in precision medicine. This labor-intensive process, traditionally reliant on manual review of complex patient records and trial eligibility criteria, is inefficient and prone to missed opportunities. Addressing this challenge, TrialMatchAI emerges as an innovative, AI-powered recommendation system designed to automate patient-to-trial matching, offering a scalable and explainable solution [6](https://arxiv.org/pdf/2505.08508v1).

## An End-to-End AI-Powered Solution for Clinical Trial Matching

TrialMatchAI leverages a robust Retrieval-Augmented Generation (RAG) framework, built upon fine-tuned, open-source Large Language Models (LLMs), to process heterogeneous clinical data. This includes both structured records (e.g., age, sex, lab results) and complex unstructured physician notes (e.g., pathology reports, prior treatments) [6](https://arxiv.org/pdf/2505.08508v1). A foundational aspect of its design is interoperability, achieved through the adoption of the Phenopackets exchange format, which standardizes patient data representation across diverse healthcare systems [6](https://arxiv.org/pdf/2505.08508v1). This standardization is crucial for ensuring consistent and comprehensive patient information, a challenge highlighted by broader efforts in clinical data element (CDE) harmonization and mCODE data standards [64](https://www.semanticscholar.org/paper/51ce73e5731db9c8906b84f54412fa6bc3750464).

The system's pipeline operates in several key stages:
1.  **Data Ingestion and Preprocessing:** Raw clinical data and trial metadata undergo extensive preprocessing. This involves Named Entity Recognition (NER) using fine-tuned BERT-based models (BioBERT, RoBERTa-large, GLiNER) and sophisticated Entity Normalization (BioSyn, GNormPlus, sieve-based methods) to standardize biomedical entities (e.g., genes, diseases, drugs) to controlled vocabularies like MeSH and Unified Medical Language System (UMLS) [6](https://arxiv.org/pdf/2505.08508v1). This step is vital for robust semantic understanding of clinical text. Patient queries are further enriched through zero-shot data augmentation using a pre-trained Phi-4 model for query expansion, enhancing retrieval versatility [6](https://arxiv.org/pdf/2505.08508v1). All processed textual data is then converted into high-dimensional dense embeddings using BGE-M3 for efficient similarity-based retrieval [6](https://arxiv.org/pdf/2505.08508v1).
2.  **Candidate Trial Retrieval:** TrialMatchAI employs a hybrid search strategy that combines BM25 lexical search for keyword-based matching with K-Nearest Neighbor (KNN) vector search for semantic relationships, both powered by Elasticsearch [6](https://arxiv.org/pdf/2505.08508v1). This dual approach ensures comprehensive retrieval, capturing trials that might be missed by purely lexical or semantic methods. An initial pre-retrieval filtering step efficiently removes obviously ineligible trials based on demographics, recruitment status, and basic criteria, optimizing subsequent processing [6](https://arxiv.org/pdf/2505.08508v1).
3.  **LLM-based Re-ranking:** A fine-tuned Gemma-2-2B model confines the initial list of candidate trials by assessing the relevance of individual eligibility criteria to the patient's profile [6](https://arxiv.org/pdf/2505.08508v1). This criterion-level re-ranking prioritizes trials with the most pertinent criteria, ensuring that the subsequent, more granular eligibility assessment focuses on the most promising matches.
4.  **Eligibility Classification and Final Ranking:** The core of TrialMatchAI's explainability lies in its criterion-level eligibility assessment, performed by a fine-tuned Phi-4 model utilizing medical Chain-of-Thought (CoT) reasoning [6](https://arxiv.org/pdf/2505.08508v1). CoT enables the model to break down complex eligibility criteria into multi-step logical inferences, providing transparent and traceable justifications for each decision (e.g., "Met," "Not Met," "Violated," "Not Violated") [6](https://arxiv.org/pdf/2505.08508v1). This granular, evidence-based approach addresses a critical need for trustworthiness in medical AI. Finally, trials are ranked based on a composite score that prioritizes satisfied inclusion criteria and minimizes exclusion violations, providing a personalized and actionable recommendation list for clinicians [6](https://arxiv.org/pdf/2505.08508v1).

## Demonstrating State-of-the-Art Performance

TrialMatchAI's performance was rigorously evaluated across synthetic and real-world datasets, consistently demonstrating high accuracy and efficiency.
*   **Synthetic Benchmarks:** On the TREC 2021 and 2022 Clinical Trials datasets, TrialMatchAI achieved over 90% recall at just 3% of the total search space, indicating its efficiency in identifying relevant trials early [6](https://arxiv.org/pdf/2505.08508v1). It showed strong ranking quality with median normalized Discounted Cumulative Gain (nDCG)@5 of 0.74 (TREC2021) and 0.82 (TREC2022), and median precision@5 of 0.8 across both datasets [6](https://arxiv.org/pdf/2505.08508v1). Notably, TrialMatchAI achieved competitive or superior performance compared to proprietary LLM-based systems like TrialGPT, despite utilizing significantly smaller, open-source models [6](https://arxiv.org/pdf/2505.08508v1).
*   **Real-World Validation:** In a real-world evaluation involving 52 metastatic cancer patients from the Netherlands Cancer Institute (NKI)'s WIDE study, TrialMatchAI achieved an overall recall of 92.3% within the top 20 recommendations, demonstrating its practical utility in complex biomarker-driven oncology trials [6](https://arxiv.org/pdf/2505.08508v1).
*   **Expert-Validated Explainability:** Expert assessment of 950 synthetic and real patient-criterion pairs confirmed the Phi-4 CoT model's high accuracy (averaging over 90%) in classifying eligibility criteria and generating explanations [6](https://arxiv.org/pdf/2505.08508v1). The rate of confabulations (hallucinations) was remarkably low, occurring in less than 1% of cases, underscoring the reliability of its reasoning [6](https://arxiv.org/pdf/2505.08508v1).

## Broader Implications and Future Directions

TrialMatchAI's open-source and locally deployable design offers a significant advantage over proprietary API-dependent systems, addressing critical concerns related to data privacy, cost, and reproducibility in healthcare [6](https://arxiv.org/pdf/2505.08508v1). This aligns with growing research advocating for more resource-efficient and accessible AI solutions in healthcare, particularly Small Language Models (SLMs) suitable for resource-constrained environments.

While other LLM-based platforms like TrialGPT [65](https://www.semanticscholar.org/paper/53247324a2d4481caba32f76c113c7a4673d4a92), the platform described by Atrium Health [66](https://www.semanticscholar.org/paper/3b7ee1aec6d1fcdc5bc8d3bb3835659bcc1b53db), and OncoLLM [67](https://www.semanticscholar.org/paper/12f9e0f9e00c38e4fbdbfabad8ecc0a9d178ad3d) also demonstrate impressive efficiency gains in patient-trial matching, TrialMatchAI's explicit focus on verifiable Chain-of-Thought reasoning and its open-source nature set a new standard for transparency and control over sensitive patient data. The integration of RAG within its framework exemplifies a broader trend in biomedical AI to enhance factual accuracy and knowledge integration.

Despite its robust performance, TrialMatchAI, like all LLM-based systems, can be susceptible to misclassifications, and its accuracy can be impacted by incomplete patient records [6](https://arxiv.org/pdf/2505.08508v1). Future work aims to enhance the system's robustness by integrating agentic workflows for dynamic verification and refinement of outputs, and by employing knowledge distillation to improve computational efficiency without sacrificing accuracy [6](https://arxiv.org/pdf/2505.08508v1). By streamlining recruitment and providing explainable, traceable decision rationales, TrialMatchAI offers a promising path to accelerate clinical trial completion and expand patient access to innovative treatments, driving forward the promise of personalized medicine.

# Conclusion

The advancements detailed demonstrate AI's pervasive and growing impact on clinical trials, from their foundational design to execution and safety monitoring. Significant progress in precision patient selection, secure and accessible data management, and robust causal inference methodologies is poised to reshape therapeutic development. Simultaneously, the application of large language models for automated knowledge synthesis and the deployment of AI in real-time patient monitoring are enhancing efficiency and safety throughout the trial lifecycle. A recurring emphasis across these diverse applications is the paramount need for explainability, uncertainty quantification, and the development of multimodal foundation models. Continued research efforts are focused on addressing challenges related to generalizability across diverse clinical populations, computational efficiency, and seamless integration into existing workflows. As these AI-driven tools mature, their rigorous validation against real-world clinical data and alignment with evolving regulatory landscapes will remain critical for their widespread adoption and for delivering on the promise of more efficient, personalized, and safer clinical research.

# References

1. Aditya Nagori, Ayush Gautam, Matthew O. Wiens, Vuong Nguyen, Nathan Kenya Mugisha, Jerome Kabakyenga, Niranjan Kissoon, John Mark Ansermino, Rishikesan Kamaleswaran (2025). *Contextual Phenotyping of Pediatric Sepsis Cohort Using Large Language Models*. ArXiv:2505.09805v1. [https://arxiv.org/pdf/2505.09805v1](https://arxiv.org/pdf/2505.09805v1)
2. Da Wu, Zhanliang Wang, Quan Nguyen, Zhuoran Xu, Kai Wang (2025). *Multimodal Integrated Knowledge Transfer to Large Language Models through Preference Optimization with Biomedical Applications*. ArXiv:2505.05736v1. [https://arxiv.org/pdf/2505.05736v1](https://arxiv.org/pdf/2505.05736v1)
3. Wei Dai, Peilin Chen, Chanakya Ekbote, Paul Pu Liang (2025). *QoQ-Med: Building Multimodal Clinical Foundation Models with Domain-Aware GRPO Training*. ArXiv:2506.00711v1. [https://arxiv.org/pdf/2506.00711v1](https://arxiv.org/pdf/2506.00711v1)
4. Peng Xia, Jinglu Wang, Yibo Peng, Kaide Zeng, Xian Wu, Xiangru Tang, Hongtu Zhu, Yun Li, Shujie Liu, Yan Lu, Huaxiu Yao (2025). *MMedAgent-RL: Optimizing Multi-Agent Collaboration for Multimodal Medical Reasoning*. ArXiv:2506.00555v1. [https://arxiv.org/pdf/2506.00555v1](https://arxiv.org/pdf/2506.00555v1)
5. Khaled Saab, Jan Freyberg, Chunjong Park, Tim Strother, Yong Cheng, Wei-Hung Weng, David G. T. Barrett, David Stutz, Nenad Tomasev, Anil Palepu, Valentin Liévin, Yash Sharma, Roma Ruparel, Abdullah Ahmed, Elahe Vedadi, Kimberly Kanada, Cian Hughes, Yun Liu, Geoff Brown, Yang Gao, Sean Li, S. Sara Mahdavi, James Manyika, Katherine Chou, Yossi Matias, Avinatan Hassidim, Dale R. Webster, Pushmeet Kohli, S. M. Ali Eslami, Joëlle Barral, Adam Rodman, Vivek Natarajan, Mike Schaekermann, Tao Tu, Alan Karthikesalingam, Ryutaro Tanno (2025). *Advancing Conversational Diagnostic AI with Multimodal Reasoning*. ArXiv:2505.04653v1. [https://arxiv.org/pdf/2505.04653v1](https://arxiv.org/pdf/2505.04653v1)
6. Majd Abdallah, Sigve Nakken, Mariska Bierkens, Johanna Galvis, Alexis Groppi, Slim Karkar, Lana Meiqari, Maria Alexandra Rujano, Steve Canham, Rodrigo Dienstmann, Remond Fijneman, Eivind Hovig, Gerrit Meijer, Macha Nikolski (2025). *TrialMatchAI: An End-to-End AI-powered Clinical Trial Recommendation System to Streamline Patient-to-Trial Matching*. ArXiv:2505.08508v1. [https://arxiv.org/pdf/2505.08508v1](https://arxiv.org/pdf/2505.08508v1)
7. Sehwan Kim, Faming Liang (2025). *Extended Fiducial Inference for Individual Treatment Effects via Deep Neural Networks*. ArXiv:2505.01995v1. [https://arxiv.org/pdf/2505.01995v1](https://arxiv.org/pdf/2505.01995v1)
8. David Svensson, Erik Hermansson, Nikolaos Nikolaou, Konstantinos Sechidis, Ilya Lipkovich (2025). *Overview and practical recommendations on using Shapley Values for identifying predictive biomarkers via CATE modeling*. ArXiv:2505.01145v1. [https://arxiv.org/pdf/2505.01145v1](https://arxiv.org/pdf/2505.01145v1)
9. Ke Zhu, Jianing Chu, Ilya Lipkovich, Wenyu Ye, Shu Yang (2025). *Doubly Robust Fusion of Many Treatments for Policy Learning*. ArXiv:2505.08092v2. [https://arxiv.org/pdf/2505.08092v2](https://arxiv.org/pdf/2505.08092v2)
10. Sofia Ek, Dave Zachariah (2025). *Learning Treatment Allocations with Risk Control Under Partial Identifiability*. ArXiv:2505.08378v1. [https://arxiv.org/pdf/2505.08378v1](https://arxiv.org/pdf/2505.08378v1)
11. Hechuan Wen, Tong Chen, Mingming Gong, Li Kheng Chai, Shazia Sadiq, Hongzhi Yin (2025). *Enhancing Treatment Effect Estimation via Active Learning: A Counterfactual Covering Perspective*. ArXiv:2505.05242v1. [https://arxiv.org/pdf/2505.05242v1](https://arxiv.org/pdf/2505.05242v1)
12. Waldemar Hahn, Jan-Niklas Eckardt, Christoph Röllig, Martin Sedlmayr, Jan Moritz Middeke, Markus Wolfien (2025). *Generating Reliable Synthetic Clinical Trial Data: The Role of Hyperparameter Optimization and Domain Constraints*. ArXiv:2505.05019v1. [https://arxiv.org/pdf/2505.05019v1](https://arxiv.org/pdf/2505.05019v1)
13. Ziyu Li, Yujian Hu, Zhengyao Ding, Yiheng Mao, Haitao Li, Fan Yi, Hongkun Zhang, Zhengxing Huang (2025). *Phenotype-Guided Generative Model for High-Fidelity Cardiac MRI Synthesis: Advancing Pretraining and Clinical Applications*. ArXiv:2505.03426v1. [https://arxiv.org/pdf/2505.03426v1](https://arxiv.org/pdf/2505.03426v1)
14. Alexandre Cotorobai, Jorge Miguel Silva, Jose Luis Oliveira (2025). *A Federated Random Forest Solution for Secure Distributed Machine Learning*. ArXiv:2505.08085v1. [https://arxiv.org/pdf/2505.08085v1](https://arxiv.org/pdf/2505.08085v1)
15. Qiming Wu, Siqi Li, Doudou Zhou, Nan Liu (2025). *Toward Fair Federated Learning under Demographic Disparities and Data Imbalance*. ArXiv:2505.09295v1. [https://arxiv.org/pdf/2505.09295v1](https://arxiv.org/pdf/2505.09295v1)
16. Haoyang Li, Jie Xu, Kyra Gan, Fei Wang, Chengxi Zang (2025). *Federated Causal Inference in Healthcare: Methods, Challenges, and Applications*. ArXiv:2505.02238v1. [https://arxiv.org/pdf/2505.02238v1](https://arxiv.org/pdf/2505.02238v1)
17. Anum Nawaz, Muhammad Irfan, Xianjia Yu, Zhuo Zou, Tomi Westerlund (2025). *Blockchain-Enabled Privacy-Preserving Second-Order Federated Edge Learning in Personalized Healthcare*. ArXiv:2506.00416v1. [https://arxiv.org/pdf/2506.00416v1](https://arxiv.org/pdf/2506.00416v1)
18. Ayoub Abraich (2025). *TV-SurvCaus: Dynamic Representation Balancing for Causal Survival Analysis*. ArXiv:2505.01785v1. [https://arxiv.org/pdf/2505.01785v1](https://arxiv.org/pdf/2505.01785v1)
19. Yingrong Wang, Anpeng Wu, Baohong Li, Ziyang Xiao, Ruoxuan Xiong, Qing Han, Kun Kuang (2025). *Sequential Treatment Effect Estimation with Unmeasured Confounders*. ArXiv:2505.09113v1. [https://arxiv.org/pdf/2505.09113v1](https://arxiv.org/pdf/2505.09113v1)
20. Winston Chen, Trenton Chang, Jenna Wiens (2025). *Conditional Front-door Adjustment for Heterogeneous Treatment Assignment Effect Estimation Under Non-adherence*. ArXiv:2505.05677v1. [https://arxiv.org/pdf/2505.05677v1](https://arxiv.org/pdf/2505.05677v1)
21. Ahmed Sayeed Faruk, Jason Sulskis, Elena Zheleva (2025). *Estimating Causal Effects in Networks with Cluster-Based Bandits*. ArXiv:2505.04200v1. [https://arxiv.org/pdf/2505.04200v1](https://arxiv.org/pdf/2505.04200v1)
22. Antonio Álvarez-López, Marcos Matabuena (2025). *Continuous Temporal Learning of Probability Distributions via Neural ODEs with Applications in Continuous Glucose Monitoring Data*. ArXiv:2505.08698v1. [https://arxiv.org/pdf/2505.08698v1](https://arxiv.org/pdf/2505.08698v1)
23. Sumyyah Toonsi, Paul Schofield, Robert Hoehndorf (2025). *Causal knowledge graph analysis identifies adverse drug effects*. ArXiv:2505.06949v1. [https://arxiv.org/pdf/2505.06949v1](https://arxiv.org/pdf/2505.06949v1)
24. Sofia Jamil, Aryan Dabad, Bollampalli Areen Reddy, Sriparna Saha, Rajiv Misra, Adil A. Shakur (2025). *GASCADE: Grouped Summarization of Adverse Drug Event for Enhanced Cancer Pharmacovigilance*. ArXiv:2505.04284v1. [https://arxiv.org/pdf/2505.04284v1](https://arxiv.org/pdf/2505.04284v1)
25. Massimiliano Pronesti, Joao Bettencourt-Silva, Paul Flanagan, Alessandra Pascale, Oisin Redmond, Anya Belz, Yufang Hou (2025). *Query-driven Document-level Scientific Evidence Extraction from Biomedical Studies*. ArXiv:2505.06186v1. [https://arxiv.org/pdf/2505.06186v1](https://arxiv.org/pdf/2505.06186v1)
26. Shuai Wang, Harrisen Scells, Bevan Koopman, Guido Zuccon (2025). *Reassessing Large Language Model Boolean Query Generation for Systematic Reviews*. ArXiv:2505.07155v2. [https://arxiv.org/pdf/2505.07155v2](https://arxiv.org/pdf/2505.07155v2)
27. Joao Torres, Catherine Mulligan, Joaquim A. Jorge, Catarina Moreira (2025). *PROMPTHEUS: A Human-Centered Pipeline to Streamline Systematic Literature Reviews with Large Language Models*. ArXiv:10.3390/info16050420. [https://www.semanticscholar.org/paper/b81dcd32fbf9bcef7a5314cf94466251dd3b7d3e](https://www.semanticscholar.org/paper/b81dcd32fbf9bcef7a5314cf94466251dd3b7d3e)
28. Brice Edelman, Jeffrey Skolnick (2025). *Valsci: an open-source, self-hostable literature review utility for automated large-batch scientific claim verification using large language models*. ArXiv:10.1186/s12859-025-06159-4. [https://www.semanticscholar.org/paper/13e079da1dba19509dfd1fd05440b1a52666603a](https://www.semanticscholar.org/paper/13e079da1dba19509dfd1fd05440b1a52666603a)
29. Chengzhang Yu, Yiming Zhang, Zhixin Liu, Zenghui Ding, Yining Sun, Zhanpeng Jin (2025). *FRAME: Feedback-Refined Agent Methodology for Enhancing Medical Research Insights*. ArXiv:2505.04649v1. [https://arxiv.org/pdf/2505.04649v1](https://arxiv.org/pdf/2505.04649v1)
30. Suhas BN, Han-Chin Shing, Lei Xu, Mitch Strong, Jon Burnsky, Jessica Ofor, Jordan R. Mason, Susan Chen, Sundararajan Srinivasan, Chaitanya Shivade, Jack Moriarty, Joseph Paul Cohen (2025). *Fact-Controlled Diagnosis of Hallucinations in Medical Text Summarization*. ArXiv:2506.00448v1. [https://arxiv.org/pdf/2506.00448v1](https://arxiv.org/pdf/2506.00448v1)
31. Adel Ammar, Anis Koubaa, Omer Nacar, Wadii Boulila (2025). *Optimizing Retrieval-Augmented Generation: Analysis of Hyperparameter Impact on Performance and Efficiency*. ArXiv:2505.08445v1. [https://arxiv.org/pdf/2505.08445v1](https://arxiv.org/pdf/2505.08445v1)
32. Gongbo Zhang, Zihan Xu, Qiao Jin, Fangyi Chen, Yilu Fang, Yi Liu, Justin F Rousseau, Ziyang Xu, Zhiyong Lu, Chunhua Weng, Yifan Peng (2025). *Leveraging long context in retrieval augmented language models for medical question answering*. ArXiv:10.1038/s41746-025-01651-w. [https://www.semanticscholar.org/paper/8bbfa19b5ef55c22b773cee948a664f0b514e0a0](https://www.semanticscholar.org/paper/8bbfa19b5ef55c22b773cee948a664f0b514e0a0)
33. Yifan Wei, Xiaoyan Yu, Tengfei Pan, Angsheng Li, Li Du (2025). *Structural Entropy Guided Agent for Detecting and Repairing Knowledge Deficiencies in LLMs*. ArXiv:2505.07184v1. [https://arxiv.org/pdf/2505.07184v1](https://arxiv.org/pdf/2505.07184v1)
34. Fahmida Liza Piya, Rahmatollah Beheshti (2025). *ConTextual: Improving Clinical Text Summarization in LLMs with Context-preserving Token Filtering and Knowledge Graphs*. ArXiv:10.48550/arXiv.2504.16394. [https://www.semanticscholar.org/paper/36bf667b489fc59ef684913a5f535f4949ca7584](https://www.semanticscholar.org/paper/36bf667b489fc59ef684913a5f535f4949ca7584)
35. S. Mohammed, J. Fiaidhi, T. Sekar, K. Kushal, S. Shankar (2025). *Investigations on using Evidence-Based GraphRag Pipeline using LLM Tailored for Answering USMLE Medical Exam Questions*. ArXiv:10.1101/2025.05.03.25325604. [https://www.semanticscholar.org/paper/573721af3692834841c3e82303a3bfabb98423b9](https://www.semanticscholar.org/paper/573721af3692834841c3e82303a3bfabb98423b9)
36. Akshaya A M, Prem Kumar S, Sam leo A, Dr.T. Kavitha (2025). *Improving LLM Accuracy and Minimizing Hallucinations with Query Refinement and Knowledge Graphs*. ArXiv:10.47392/irjaem.2025.0189. [https://www.semanticscholar.org/paper/fab0506cd76a8c4308f3643d6af8a9e769f19af7](https://www.semanticscholar.org/paper/fab0506cd76a8c4308f3643d6af8a9e769f19af7)
37. Larissa Montenegro, Luis M. Gomes, José Machado (2025). *What We Know About the Role of Large Language Models for Medical Synthetic Dataset Generation*. ArXiv:10.3390/ai6060109. [https://www.semanticscholar.org/paper/9efdd09bb8c967052f7e035f45f4e41fad79c7d0](https://www.semanticscholar.org/paper/9efdd09bb8c967052f7e035f45f4e41fad79c7d0)
38. Dario Garcia-Gasulla, Jordi Bayarri-Planas, Ashwin Kumar Gururajan, Enrique Lopez-Cuena, Adrian Tormos, Daniel Hinjos, Pablo Bernabeu-Perez, Anna Arias-Duart, Pablo Agustin Martin-Torres, Marta Gonzalez-Mallo, Sergio Alvarez-Napagao, Eduard Ayguadé-Parra, Ulises Cortés (2025). *The Aloe Family Recipe for Open and Specialized Healthcare LLMs*. ArXiv:2505.04388v1. [https://arxiv.org/pdf/2505.04388v1](https://arxiv.org/pdf/2505.04388v1)
39. Aoran Gan, Hao Yu, Kai Zhang, Qi Liu, Wenyu Yan, Zhenya Huang, Shiwei Tong, Guoping Hu (2025). *Retrieval Augmented Generation Evaluation in the Era of Large Language Models: A Comprehensive Survey*. ArXiv:10.48550/arXiv.2504.14891. [https://www.semanticscholar.org/paper/79e57387a664a5d7b128b2790a8f38f827e09124](https://www.semanticscholar.org/paper/79e57387a664a5d7b128b2790a8f38f827e09124)
40. Hyunjae Kim, Hyeon Hwang, Jiwoo Lee, Sihyeon Park, Dain Kim, Taewhoo Lee, Chanwoong Yoon, Jiwoong Sohn, Jungwoo Park, Olga Reykhart, T. Fetherston, Donghee Choi, Soo Heon Kwak, Qingyu Chen, Jaewoo Kang (2025). *Small language models learn enhanced reasoning skills from medical textbooks*. ArXiv:10.1038/s41746-025-01653-8. [https://www.semanticscholar.org/paper/7445f3d7a16d992029585e93704ec44f0e99e43e](https://www.semanticscholar.org/paper/7445f3d7a16d992029585e93704ec44f0e99e43e)
41. Muskan Garg, Shaina Raza, Shebuti Rayana, Xingyi Liu, Sunghwan Sohn (2025). *The Rise of Small Language Models in Healthcare: A Comprehensive Survey*. ArXiv:10.48550/arXiv.2504.17119. [https://www.semanticscholar.org/paper/d0e6b0a43edec2424005ee900c6d657597bd7d16](https://www.semanticscholar.org/paper/d0e6b0a43edec2424005ee900c6d657597bd7d16)
42. Zhaid Khan (2025). *Real-Time AI Systems for ICU Risk Monitoring*. ArXiv:10.36948/ijfmr.2025.v07i02.41428. [https://www.semanticscholar.org/paper/c84ef7adb1d027762e941a9a8f2f6caec6366490](https://www.semanticscholar.org/paper/c84ef7adb1d027762e941a9a8f2f6caec6366490)
43. Lo Pang-Yun Ting, Hong-Pei Chen, An-Shan Liu, Chun-Yin Yeh, Po-Lin Chen, Kun-Ta Chuang (2025). *Early Detection of Patient Deterioration from Real-Time Wearable Monitoring System*. ArXiv:2505.01305v1. [https://arxiv.org/pdf/2505.01305v1](https://arxiv.org/pdf/2505.01305v1)
44. Kateryna Nesvit, Ellie Gordon, Murray Gordon (2025). *Early Detection of Cardiovascular Diseases Using an AI Mobile Application and Smartwatch Devices*. ArXiv:10.69793/ijmcs/02.2025/gordon. [https://www.semanticscholar.org/paper/59ea60ef5fb24d99ece1d1d77c5e1b74b534946e](https://www.semanticscholar.org/paper/59ea60ef5fb24d99ece1d1d77c5e1b74b534946e)
45. Hasan Mahmud Sozib (2025). *Wearable AI for Cardiovascular Health Monitoring: Enabling Early Detection and Prevention*. ArXiv:10.32996/jcsts.2025.7.2.30. [https://www.semanticscholar.org/paper/f921dae76cfdf6155f685fb355208af786292fb4](https://www.semanticscholar.org/paper/f921dae76cfdf6155f685fb355208af786292fb4)
46. Pratyush Jagdish Birole, Garima Jain, Sanat Jain, Vedant Kanoje, Subhranil Bhattacharya, Harsh Kanoje (2025). *Bit-Heart: Wearable Device for Healthcare Diagnosis Employing IOT and Machine Learning*. ArXiv:10.1109/InCACCT65424.2025.11011406. [https://www.semanticscholar.org/paper/dce80322afb5ca2bc91de58b4ba049cbf2c800fa](https://www.semanticscholar.org/paper/dce80322afb5ca2bc91de58b4ba049cbf2c800fa)
47. N. Almujally, Danyal Khan, Naif Al Mudawi, Mohammed Alonazi, Haifa F. Alhasson, Ahmad Jalal, Hui Liu (2025). *Wearable sensors-based assistive technologies for patient health monitoring*. ArXiv:10.3389/fbioe.2025.1437877. [https://www.semanticscholar.org/paper/e12e777b87213cc001119eb078eff21ff0b4583f](https://www.semanticscholar.org/paper/e12e777b87213cc001119eb078eff21ff0b4583f)
48. Yayun Du, Jianyu Gu, Shiyuan Duan, J. Trueb, A. Tzavelis, Hee-Sup Shin, Hany M Arafa, Xiuyuan Li, Yonggang Huang, Andrew N Carr, Charles R Davies, John A. Rogers (2025). *A skin-interfaced wireless wearable device and data analytics approach for sleep-stage and disorder detection.*. ArXiv:10.1073/pnas.2501220122. [https://www.semanticscholar.org/paper/cedad978a16f6e7a714e1a9edf88ef0fa49e99a4](https://www.semanticscholar.org/paper/cedad978a16f6e7a714e1a9edf88ef0fa49e99a4)
49. Kaustav Sanyal, Rupesh Dutta, Yeasin Mallick (2025). *Personalized Cardiovascular Monitoring via Real-Time Smartwatch Data and Anomaly Detection*. ArXiv:10.56975/ijcrt.v13i5.286606. [https://www.semanticscholar.org/paper/5e01ec700d8a6bc66926c32536278ea24a3f4a6c](https://www.semanticscholar.org/paper/5e01ec700d8a6bc66926c32536278ea24a3f4a6c)
50. Nishanth Joseph Paulraj (2025). *AI Pipeline for Real-Time Health Event Detection from Wearable Devices*. ArXiv:10.37745/ejcsit.2013/vol13n161124. [https://www.semanticscholar.org/paper/3a3479d7bbce357bb715d3f431ec6bd2f448580a](https://www.semanticscholar.org/paper/3a3479d7bbce357bb715d3f431ec6bd2f448580a)
51. M. Joshi, F. Iqbal, Mansour Sharabiani, H. Ashrafian, S. Arora, Kenny McAndrew, Sadia Khan, Graham Cooke, A. Darzi (2025). *Performance of Continuous Digital Monitoring of Vital Signs with a Wearable Sensor in Acute Hospital Settings*. ArXiv:10.3390/s25092644. [https://www.semanticscholar.org/paper/7bf89fc7c68bbe44680dc167b12f587dc04de185](https://www.semanticscholar.org/paper/7bf89fc7c68bbe44680dc167b12f587dc04de185)
52. Yi Wang, Weihua Li (2025). *Integrating Multimodal EHR Data for Mortality Prediction in ICU Sepsis Patients*. ArXiv:10.1002/sim.70060. [https://www.semanticscholar.org/paper/b847ce14966bdb9af77501f0850f45b4411f85e0](https://www.semanticscholar.org/paper/b847ce14966bdb9af77501f0850f45b4411f85e0)
53. M. C. Sekhar, Pasam Naga Kavitha, B.N.V. Uma Shankar, Amrutavalli Aakula, Divya Boya (2025). *MedFusionAI: A Deep Learning Framework for Multi-Modal Health Data Fusion to Predict Chronic Disease Risks*. ArXiv:10.22399/ijcesen.2159. [https://www.semanticscholar.org/paper/0b58e33e5512543ac6fb3c30644ae8b3a54d76c0](https://www.semanticscholar.org/paper/0b58e33e5512543ac6fb3c30644ae8b3a54d76c0)
54. Nura Ikhalea, Ernest Chinonso Chianumba, Ashiata Yetunde Mustapha, Adelaide Yeboah Forkuo (2022). *A Conceptual Framework for AI-Driven Early Detection of Chronic Diseases Using Predictive Analytics*. ArXiv:10.54660/.ijfmr.2022.3.1.89-104. [https://www.semanticscholar.org/paper/0a5e758c6f23306494bbb4fca16441469a451935](https://www.semanticscholar.org/paper/0a5e758c6f23306494bbb4fca16441469a451935)
55. Sai Kalyani (2025). *AI-Powered Early Diagnosis Systems Using Multi-Modal Healthcare Data*. ArXiv:10.37082/ijirmps.v13.i2.232445. [https://www.semanticscholar.org/paper/9b944dacca2a85a6ed715a62e2a4b139f841b6db](https://www.semanticscholar.org/paper/9b944dacca2a85a6ed715a62e2a4b139f841b6db)
56. [Metadata not found for ID: 10.54660/.ijfmr.2023.4.1.1084-1094] ArXiv:10.54660/.ijfmr.2023.4.1.1084-1094. [https://arxiv.org/abs/10.54660/.ijfmr.2023.4.1.1084-1094](https://arxiv.org/abs/10.54660/.ijfmr.2023.4.1.1084-1094)
57. Marco Voegeli, Sonia Laguna, Heike Leutheuser, Marc Pfister, Marie-Anne Burckhardt, Julia E. Vogt (2025). *Beyond Glucose-Only Assessment: Advancing Nocturnal Hypoglycemia Prediction in Children with Type 1 Diabetes*. ArXiv:10.48550/arXiv.2504.09299. [https://www.semanticscholar.org/paper/3bd03ada8c56c8e948dbfc01fc39461048acdd22](https://www.semanticscholar.org/paper/3bd03ada8c56c8e948dbfc01fc39461048acdd22)
58. Tolulope O. Kolawole, Ashiata Yetunde Mustapha, Akachukwu Obianuju Mbata, Busayo Olamide Tomoh, Adelaide Yeboah Forkuo, MariaTheresa Chinyeaka Kelvin-Agwu (2025). *A Systematic Review of Predictive Analytics Applications in Early Disease Detection and Diagnosis*. ArXiv:10.47191/etj/v10i03.35. [https://www.semanticscholar.org/paper/d80607f5e0a19f89d84ec21e888b839621426b66](https://www.semanticscholar.org/paper/d80607f5e0a19f89d84ec21e888b839621426b66)
59. Cristiano Paschoalim de Almeida, H. Bernardino, Jairo Francisco de Souza, Luciana Conceição Dias Campos (2025). *Real-Time Heart Failure Prediction: An Approach for Ambient Assisted Living*. ArXiv:10.5753/sbsi.2025.245972. [https://www.semanticscholar.org/paper/c5eb9a6643af5bd98292d3b690e70aed9234f049](https://www.semanticscholar.org/paper/c5eb9a6643af5bd98292d3b690e70aed9234f049)
60. Dhruvi Manish Bhatt, Ankita Gandhi, Sanjay Agal (2025). *Self-Adaptive Sensor Fault Detection in IoT Health Monitoring Using Federated Learning and Lightweight Transformers*. ArXiv:10.52783/jisem.v10i41s.7838. [https://www.semanticscholar.org/paper/2f8956fea8ffe3f71c50f0a8dc192ad8af9d5496](https://www.semanticscholar.org/paper/2f8956fea8ffe3f71c50f0a8dc192ad8af9d5496)
61. M. Hizem, Leila Bousbia, Yassmine Ben Dhiab, Mohamed Ould-Elhassen Aoueileyine, R. Bouallègue (2025). *Reliable ECG Anomaly Detection on Edge Devices for Internet of Medical Things Applications*. ArXiv:10.3390/s25082496. [https://www.semanticscholar.org/paper/19e05c46bf3d30aadfb603599b511fba684dcd6a](https://www.semanticscholar.org/paper/19e05c46bf3d30aadfb603599b511fba684dcd6a)
62. L. Julián Lechuga López, Shaza Elsharief, Dhiyaa Al Jorf, Firas Darwish, Congbo Ma, Farah E. Shamout (2025). *Uncertainty Quantification for Machine Learning in Healthcare: A Survey*. ArXiv:2505.02874v1. [https://arxiv.org/pdf/2505.02874v1](https://arxiv.org/pdf/2505.02874v1)
63. Jiarun Liu, Hong-Yu Zhou, Weijian Huang, Hao Yang, Dongning Song, Tao Tan, Yong Liang, Shanshan Wang (2025). *BioVFM-21M: Benchmarking and Scaling Self-Supervised Vision Foundation Models for Biomedical Image Analysis*. ArXiv:2505.09329v1. [https://arxiv.org/pdf/2505.09329v1](https://arxiv.org/pdf/2505.09329v1)
64. Yan Leyfman, Arturo Loaiza-Bonilla, Viviana Cortiana, Ertugrul Tuysuz, S. Kurnaz, Oz Huner, Dersu Giritlioğlu, Juan Pablo Noel Meza, C. Culcuoglu (2025). *Performance evaluation of an AI-powered system for clinical trial eligibility using mCODE data standards.*. ArXiv:10.1200/jco.2025.43.16_suppl.e13621. [https://www.semanticscholar.org/paper/51ce73e5731db9c8906b84f54412fa6bc3750464](https://www.semanticscholar.org/paper/51ce73e5731db9c8906b84f54412fa6bc3750464)
65. Joey Chan, Qiao Jin, Nicholas Wan, C. Floudas, Elisabetta Xue, Zhiyong Lu (2025). *Recommending Clinical Trials for Online Patient Cases using Artificial Intelligence*. ArXiv:10.48550/arXiv.2504.20059. [https://www.semanticscholar.org/paper/53247324a2d4481caba32f76c113c7a4673d4a92](https://www.semanticscholar.org/paper/53247324a2d4481caba32f76c113c7a4673d4a92)
66. Jai Narendra Patel, Michael Cyrus Maher, Robyn Yano, Patrick Jongeneel, Victoria Morris, Wei Sha, Ferdous Ahmed, Melissa Bacchus, Dazhi Liu, Nataya Francis, Pranav Singh, Ognjen Nikolic, Anne-Marie Meyer, Michael Wang, C. Farhangfar, Phil Butera (2025). *Enhancing clinical trial screening with a comprehensive large language model platform.*. ArXiv:10.1200/jco.2025.43.16_suppl.e13674. [https://www.semanticscholar.org/paper/3b7ee1aec6d1fcdc5bc8d3bb3835659bcc1b53db](https://www.semanticscholar.org/paper/3b7ee1aec6d1fcdc5bc8d3bb3835659bcc1b53db)
67. Grace Westerman, Claire T Verhagen, Haley Heaviland, Erin Lynch, Olivia Brandenburg, Jennifer Adams Patton, Regina M. Schwind, Ben George, Anai Kothari (2025). *Enterprise-level AI screening for oncology trials: Improving patient identification with OncoLLM.*. ArXiv:10.1200/jco.2025.43.16_suppl.e13706. [https://www.semanticscholar.org/paper/12f9e0f9e00c38e4fbdbfabad8ecc0a9d178ad3d](https://www.semanticscholar.org/paper/12f9e0f9e00c38e4fbdbfabad8ecc0a9d178ad3d)
